leadf
logo-loader
viewCytoDyn Inc.

CytoDyn to submit request for pre-submission meetings in U.K. for Leronlimab

CytoDyn Inc (OTCQB: CYDY) CEO Nader Pourhassan shared news with Steve Darling from Proactive that the company has started the process of requesting meetings in the U.K. for leronlimab as an HIV treatment as well as for emergency approval of leronlimab for COVID-19 patients with mild-to-moderate symptoms.

Pourhassan telling Proactive what the process will be and he also addressed some recent comments made about the company.

Quick facts: CytoDyn Inc.

Price: 2.355 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.34 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

CytoDyn provide update on their path to approval for treatment of COVID-19

CytoDyn (OTCQB: CYDY) CEO Nader Pourhassan joined Steve Darling from Proactive to provide an update on how and when they expect to have approval for Leronlimab for Covid treatment.  Pourhassan also told Proactive about what the recent decision by the FDA to approve Remdesivir as a...

5 days, 19 hours ago

2 min read